

# Cynthia A Lemere

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3824305/publications.pdf>

Version: 2024-02-01

65  
papers

13,557  
citations

109321

35  
h-index

168389

53  
g-index

79  
all docs

79  
docs citations

79  
times ranked

16921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amyloid- $\beta$ protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. <i>Nature Medicine</i> , 2008, 14, 837-842.	30.7	3,225
2	Complement and microglia mediate early synapse loss in Alzheimer mouse models. <i>Science</i> , 2016, 352, 712-716.	12.6	2,237
3	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. <i>Immunity</i> , 2017, 47, 566-581.e9.	14.3	1,741
4	The Swedish mutation causes early-onset Alzheimer's disease by $\beta$ -secretase cleavage within the secretory pathway. <i>Nature Medicine</i> , 1995, 1, 1291-1296.	30.7	529
5	The E280A presenilin 1 Alzheimer mutation produces increased $A\beta_{42}$ deposition and severe cerebellar pathology. <i>Nature Medicine</i> , 1996, 2, 1146-1150.	30.7	489
6	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 3, 1.	6.2	424
7	Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	401
8	The epigenetics of aging and neurodegeneration. <i>Progress in Neurobiology</i> , 2015, 131, 21-64.	5.7	334
9	Can Alzheimer disease be prevented by amyloid- $\beta$ immunotherapy?. <i>Nature Reviews Neurology</i> , 2010, 6, 108-119.	10.1	329
10	Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. <i>Journal of Neuroscience</i> , 2015, 35, 13029-13042.	3.6	286
11	Inflammatory Responses to Amyloidosis in a Transgenic Mouse Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2001, 158, 1345-1354.	3.8	275
12	Complement C3 Deficiency Leads to Accelerated Amyloid $\beta$ Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice. <i>Journal of Neuroscience</i> , 2008, 28, 6333-6341.	3.6	274
13	Intraneuronal $A\beta_{42}$ accumulation in Down syndrome brain. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 88-102.	3.0	237
14	Down syndrome and Alzheimer's disease: Common pathways, common goals. <i>Alzheimer's and Dementia</i> , 2015, 11, 700-709.	0.8	218
15	Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. <i>Current Alzheimer Research</i> , 2015, 13, 18-29.	1.4	191
16	Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased $A\beta$ Plaque Accumulation in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e53275.	2.5	171
17	Immunotherapy for Alzheimer's disease: hoops and hurdles. <i>Molecular Neurodegeneration</i> , 2013, 8, 36.	10.8	162
18	Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease. <i>American Journal of Pathology</i> , 2000, 156, 489-499.	3.8	157

#	ARTICLE	IF	CITATIONS
19	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 98.	6.2	152
20	Evidence for peripheral clearance of cerebral A $\beta$ 2 protein following chronic, active A $\beta$ 2 immunization in PSAPP mice. <i>Neurobiology of Disease</i> , 2003, 14, 10-18.	4.4	151
21	Reduced A $\beta$ -Amyloid Production and Increased Inflammatory Responses in Presenilin Conditional Knock-out Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 46907-46914.	3.4	148
22	Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A $\beta$ by microglia. <i>Glia</i> , 2012, 60, 993-1003.	4.9	136
23	<i>In Vivo</i> Detection of Age- and Disease-Related Increases in Neuroinflammation by <sup>18</sup> F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice. <i>Journal of Neuroscience</i> , 2015, 35, 15716-15730.	3.6	110
24	Intraneuronal Abeta42 accumulation in Down syndrome brain. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 88-102.	3.0	109
25	Pyroglutamate-3 Amyloid-A $\beta$ 2 Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models. <i>American Journal of Pathology</i> , 2013, 183, 369-381.	3.8	102
26	Traumatic Brain Injury in Aged Mice Induces Chronic Microglia Activation, Synapse Loss, and Complement-Dependent Memory Deficits. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3753.	4.1	98
27	Microbiota in Neuroinflammation and synaptic dysfunction: a focus on Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 19.	10.8	89
28	Characterization of A $\beta$ 11-40/42 peptide deposition in Alzheimer's disease and young Down syndrome brains: implication of N-terminally truncated A $\beta$ 2 species in the pathogenesis of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2006, 112, 163-174.	7.7	87
29	Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. <i>Progress in Brain Research</i> , 2009, 175, 83-93.	1.4	74
30	Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. <i>Neurobiology of Aging</i> , 2002, 23, 991-1000.	3.1	71
31	Passive Immunization against Pyroglutamate-3 Amyloid-A $\beta$ 2 Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2012, 10, 265-270.	1.4	63
32	MER5101, a Novel A $\beta$ 1-15:DT Conjugate Vaccine, Generates a Robust Anti-A $\beta$ 2 Antibody Response and Attenuates A $\beta$ 2 Pathology and Cognitive Deficits in APP <sup>swe</sup> /PS1 <sup>E9</sup> Transgenic Mice. <i>Journal of Neuroscience</i> , 2013, 33, 7027-7037.	3.6	50
33	Space-like 56Fe irradiation manifests mild, early sex-specific behavioral and neuropathological changes in wildtype and Alzheimer's-like transgenic mice. <i>Scientific Reports</i> , 2019, 9, 12118.	3.3	49
34	An anti-pyroglutamate-3 A $\beta$ 2 vaccine reduces plaques and improves cognition in APP <sup>swe</sup> /PS1 <sup>E9</sup> mice. <i>Neurobiology of Aging</i> , 2015, 36, 3187-3199.	3.1	45
35	Passive A $\beta$ 2 Immunotherapy: Current Achievements and Future Perspectives. <i>Molecules</i> , 2018, 23, 1068.	3.8	41
36	Immunotherapy targeting pyroglutamate-3 A $\beta$ 2: prospects and challenges. <i>Molecular Neurodegeneration</i> , 2016, 11, 48.	10.8	38

#	ARTICLE	IF	CITATIONS
37	Anti-A $\beta$ antibodies incapable of reducing cerebral A $\beta$ oligomers fail to attenuate spatial reference memory deficits in J20 mice. <i>Neurobiology of Disease</i> , 2015, 82, 372-384.	4.4	37
38	Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2018, 86, 1-15.	2.2	31
39	Tau immunization: a cautionary tale?. <i>Neurobiology of Aging</i> , 2015, 36, 1316-1332.	3.1	28
40	Effector function of anti-pyroglutamate-3 A $\beta$ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 12.	6.2	26
41	Focused ultrasound with anti-pGlu3 A $\beta$ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. <i>Journal of Controlled Release</i> , 2021, 336, 443-456.	9.9	21
42	A beneficial role for IL-1 $\beta$ in Alzheimer disease?. <i>Journal of Clinical Investigation</i> , 2007, 117, 1483-1485.	8.2	18
43	Development of the clinical candidate PBD-C06, a humanized pGlu3-A $\beta$ -specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020, 10, 3294.	3.3	17
44	Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme. <i>Neuroscience</i> , 2020, 443, 30-43.	2.3	14
45	Phosphorylated A $\beta$ peptides in human Down syndrome brain and different Alzheimer's-like mouse models. <i>Acta Neuropathologica Communications</i> , 2020, 8, 118.	5.2	14
46	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain A $\beta$ Pathology in Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11791.	4.1	10
47	Long-Term Sex- and Genotype-Specific Effects of 56Fe Irradiation on Wild-Type and APP <sup>swe</sup> /PS1 <sup>dE9</sup> Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13305.	4.1	10
48	Acute Effects of Focused Ultrasound-Induced Blood-Brain Barrier Opening on Anti-Pyroglu3 A $\beta$ Antibody Delivery and Immune Responses. <i>Biomolecules</i> , 2022, 12, 951.	4.0	9
49	Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2018, 9, 279-286.	0.8	8
50	Deposition of phosphorylated amyloid $\beta$ in brains of aged nonhuman primates and canines. <i>Brain Pathology</i> , 2018, 28, 427-430.	4.1	8
51	Active Amyloid- $\beta$ Vaccination Results in Epigenetic Changes in the Hippocampus of an Alzheimer's Disease-Like Mouse Model. <i>Current Alzheimer Research</i> , 2019, 16, 861-870.	1.4	4
52	P4-264: ARE ANTI-ABETA AGGREGATE-PREFERRING ANTIBODIES THE FUTURE FOR AD IMMUNOTHERAPY?. , 2014, 10, P881-P882.		2
53	BrightFocus Alzheimer's Fast Track 2019. <i>Molecular Neurodegeneration</i> , 2019, 14, 48.	10.8	1
54	<i>APOE</i> $\epsilon$ 4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome—Implications for Clinical Trials and Treatments for All. <i>JAMA Neurology</i> , 2021, 78, 913.	9.0	1

#	ARTICLE	IF	CITATIONS
55	F3-01-02: Alzheimer's disease and Down syndrome. , 2013, 9, P513-P513.		0
56	O2-07-03: Complement C3-deficiency preserves hippocampal synapses and neurons with aging and improves learning and memory compared to WT mice. , 2013, 9, P328-P328.		0
57	S4-02-03: COMPLEMENT IN ALZHEIMER'S DISEASE: LESSONS FROM C3-DEFICIENT MICE. , 2014, 10, P240-P240.		0
58	P3-108: Beneficial Effects of Anti-Inflammatory, RNS60, in Aged APPSWE/PS1DE9 Mice. , 2016, 12, P860-P860.		0
59	[F4â€“06â€“02]: UPDATE OF THE AMYLOID HYPOTHESIS: COMPLEMENT MODULATES THE GLIAL RESPONSE TO A $\beta$ <sub>1-42</sub> PLAQUES AND MEDIATES SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P1218.	0.8	0
60	P1â€“099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATEâ€“A $\beta$ <sub>1-42</sub> SPECIFIC ANTIBODY (PBDâ€“M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASEâ€“LIKE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P309.	0.8	0
61	A novel inducible complement C3 conditional knockout mouse model: Generation and characterization. Alzheimer's and Dementia, 2020, 16, e047192.	0.8	0
62	Global C3 lowering alleviates hippocampal dysfunction and cognitive impairment in aged mice. Alzheimer's and Dementia, 2021, 17, e058736.	0.8	0
63	Focus Ultrasoundâ€“Induced Bloodâ€“Brain Barrier opening enhances antiâ€“pGlu3 A $\beta$ <sub>1-42</sub> mAb delivery and amyloidâ€“beta plaque clearance. Alzheimer's and Dementia, 2021, 17, e058725.	0.8	0
64	Vaccination against the broadly expressed microbial antigen PNAG prevents cognitive decline in the APP-PS1 mouse model of Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053793.	0.8	0
65	Global complement C3 lowering in adult mice protects hippocampal synaptic function.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e057867.	0.8	0